Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART

Current HIV Research

Volumn 5, Issue 2, 2007, Pages 235-250

  Wang, Yuan Min ^a,e   Dyer, Wayne B ^b   Workman, Cassy ^c   Wang, Bin ^a   Peng, Ng Kee ^d   Lachireddy, Kishen ^b   Chew, Choo Beng ^a   Sullivan, John ^b   Saksena, Nitin K ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c Ground Zero Medical Centre   (Australia)

^d Tissue Typing Laboratory   (Australia)

^e CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Drug resistance; HAART; HIV 1; Structured treatment interruption (STI); Viral evolution

Indexed keywords

DIDANOSINE; HYDROXYUREA; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS ENVELOPE PROTEIN; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ADULT; BLOOD CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MALE; MOLECULAR EVOLUTION; PHYLOGENY; PROVIRUS; REVIEW; TREATMENT FAILURE; VIREMIA; VIRUS CULTURE; VIRUS GENE; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; ANTIBIOTIC RESISTANCE; ARTICLE; CULTURE TECHNIQUE; DRUG ADMINISTRATION; DRUG EFFECT; ENVELOPE GENE; GENETICS; METHODOLOGY; MIDDLE AGED; MOLECULAR GENETICS; MONONUCLEAR CELL; PLASMA; SEQUENCE ANALYSIS; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL CULTURE TECHNIQUES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GENE PRODUCTS, ENV; GENES, ENV; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; PLASMA; SEQUENCE ANALYSIS, PROTEIN; VIRAL LOAD; VIRUS REPLICATION;

EID: 33947573174     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016207780077039     Document Type: Review

References (29)

1. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JAM, Baseler M, Lloyd AL, Nowak MA, Fauci AS. (1997). Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the National Academy of Sciences of United States of America. 94:13193-13197.
2. Coombs RW, Speck CE, Hughes JP, Lee W, Sampoleo R, Ross SO, Dragavon J, Peterson G, Houton TM, Collier AC, Corey L, Koutsky L, Krieger JN. (1998). Association between Culturable Human Immunodeficience Virus Type 1 (HIV-1) in Semen and HIV-1 RNA Levels in Semen and Blood: Evidence for Compartmentalization of HIV-1 between Semen and Blood. Journal of Infectious Diseases. 177: 320-330.
3. Delwart EL, Pan H, Neumann A, Markowitz M. (1998). Rapid, transient changes at the env locus of plasma HIV-1 population during the emergence of protease inhibitor resistance. Journal of Virology. 72:2416-2421.
4. Dornadula G, Nunnari G, Vanella M, Roman J, Babinchak T, Desimone J, Braffman M, Zhang H, Pomerantz RJ. (2001). Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. Journal of Infectious Diseases. 83:1682-1687.
5. Felsenstein, J. PHYLIP (Phylogeny Inference Package), version 3.56c. 1992. Seattle: University of Washington.
6. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1295-1300.
7. Furtado MR, Murphy R, Wolinsky SM. (1993). Quantification of human immunodeficiency virus type 1 tat mRNA as a marker for assessing the efficacy of antiretroviral therapy. Journal of Infectious Diseases. 167:213-216.
8. Gunthard HF, Frost SD, Leigh-Brown AJ, Ignacio CC, Kee K, Perelson AS, Spina CA, Havlir DV, Hezareh M, Looney DJ, Richman DD, Wong JK. (1999). Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. Journal of Virology. 73:9404-9412.
9. Gunthard HF, Havlir DV, Fiscus S, Zhang ZQ, Eton J, Mellors J, Gulick R, Frost SD, Brown AJ, Schleif W, Valentine F, Jonas L, Meibohm A, Ignacio CC, Isaacs R, Gamagami R, Emini E, Haase A, Richman DD, Wong JK. (2001). Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after supression of viremia for 2 years. Journal of Infectious Diseases. 183:1318-1327.
10. Martinez MA, Cabana M, Ibanez A, Clotet B, Arno A, Lidia R. (1999). Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology. 256:180-187.
11. Palmer S, Shaferm RW, Merigan TC. (1999). Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS. 13:661-667.
12. Pathak KV, Hu WS. (1998). Mutation, recombination, and dynamics of HIV-1 in vivo. In: Human immunodeficiency Viruses: Biology, Immunology, and Molecular Biology (Nitin Saksena, Ed.), Medical Systems SPA, pp. 299-330.
13. Pellegrin I, Izopet J, Reynes J, Fleury H, segondy M. (1999). Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. AIDS. 13:1705-1709.
14. Pomerantz RJ. (2002). Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. Clinical Infectious Diseases. 34:91-97.
15. Powdely WG, Landay A, Lederman MM. (1998). Recovery of the immune system with anti-retroviral therapy: The end of opportunism. Journal of the American Medical Association. 280:72-77.
16. Romano L, Venturi G, Carucci M, Milito AD, Valensin PE, Zazzi M. (1999). Evaluation of cell-free and cell-associated peripheral blood human immunodeficiency virus type 1 RNA response to antiretroviral therapy. Journal of Infectious Diseases. 179:361-366.
17. Rose RE, Gong YF, Greytok JA, Bechtold CM, Terry BJ, Alain M, Colonno RJ, Lin PF. (1996). HIV-1 viral background plays a major role in the development of resistance to protease inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 93:1648-1653.
18. Saksena NK, Potter SJ. (2003). Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy. AIDS Reviews 5:3-18.
19. Schrager LK, D'Souza MP. (1998). Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. Journal of the American Medical Association. 280:67-71.
20. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W. (1994). Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Research. 22:4673-4680.
21. Venturi G, Catucci M, Romano L, Leoncini F, Valensin PE, Zazzi M. (2000). Antiretroviral Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Protease from Paired Cerebrospinal Fluid and Plasma samples. Journal of Infectious Diseases. 181:740-745.
22. Verhofstede C, Reniers S, Van Wanzeele F, Plum J. (1994). Evaluation of proviral copy number and plasma RNA level as early indicators of progression in HIV-1 infection: correlation with virological and immunological markers of disease. AIDS. 8:1421-1427.
23. Wang B, Ge YC, Palasanthiran P, Xiang SH, Ziegler J, Dwyer DE, Saksena NK. (1996). Gene defects clustered at the C-terminus of the vpr gene of HIV-1 long-term non-progressing mother-child pair: in vivo evolution of vpr quasispecies in blood and plasma. Virology. 223:224-232.
24. Wang YM, Dyer WB, Workman C, Wang B, Sullivan J, Saksena NK. (2000). Molecular evidence for drug-induced compartmentalization of HIV-1 quasispecies in a patient with periodic changes in HAART. AIDS. 14:2265-2272.
25. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, Richman DD. (1997). In vivo Compartmentalization of Human Immunodeficiency virus: Evidence from the Examination of pot Sequences from Autopsy Tissues. Journal of Virology. 71:2059-2071.
26. Yahi N, Tamalet C, Tourres C, Tivoli N, Ariasi F, Volot F, Gastaut JA, Gallais H, Moreau J, Fantini J. (1999). Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. Journal of Clinical Microbiology. 37:4099-4106.
27. Young B, Johnson S, Bahktiari M Shugart D, Young RK, Allen M, Ramey RR 2nd, Kuritzkes DR. (1998). Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. Journal of infectious Diseases. 178:1497-1501.
28. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. (1998). Loss of viral fitness associated with multiple gag and gag-pol processing defects in HIV-1 variants selected for resistance to protease inhibitors in vivo. Journal of Virology. 72:3300-3306.
29. Zhu T, Wang N, Carr A. (1996). Genetic Characterization of Human Immunodeficiency Virus Type 1 in Blood and Genital Secretions: Evidence for Viral Compartmentalization and Selection during Sexual Transmission. Journal of Virology. 70:3098-3107.